Myeloproliferative Neoplasms
Latest News
Advertisement
Latest Videos
Advertisement
More News
Ruben A. Mesa, MD, FACP, discussed the current state of treatment in essential thrombocythemia and polycythemia vera, the underutilization of fedratinib in myelofibrosis, and emerging JAK inhibitors on the horizon.
Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.
Mutually exclusive gene combinations were observed between specific subtypes of patients with myelodysplastic syndromes and myeloproliferative neoplasms and most other types of MDS/MPNs that have an impact on patient outcomes.
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.
Ronald Hoffman, MD, discusses the safety profile of the first-in-class synthetic hepcidin mimetic agent PTG-300 in patients with polycythemia vera.
Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).
The FDA has approved an oral combination comprised of decitabine and cedazuridine for the treatment of select adult patients with myelodysplastic syndromes.
Advances in the Management of MPNs
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Essential Thrombocythemia: Treatment Optimization
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Classifying Patients With Essential Thrombocythemia
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Primary Myelofibrosis: Trials of Interest
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
JAK2 Inhibitor Selection for Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Fedratinib for Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Ruxolitinib and Surgical Interventions
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Ruxolitinib for Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Treating Intermediate/High-Risk Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Management of Low-Risk Primary Myelofibrosis
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Primary Myelofibrosis: Risk Stratification
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: PROUD-PV Trial
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Utilization of Ruxolitinib for Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Ruxolitinib Trial Data
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Switching Therapy
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Treatment Options for High-Risk Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Management of Low-Risk Polycythemia Vera
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Polycythemia Vera: Monitoring Patients
ByHarry P. Erba, MD, PhD, Duke Cancer Institute,Krisstina Gowin, DO, University of Arizona Cancer Center,Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center,Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center,Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
5